Abstract
Summary
Arthritis Monoclonal Antibodies are a group of complex and effective biological agents used to treat arthritis and other immune-mediated inflammatory diseases
LPI (LP Information)' newest research report, the “Arthritis Monoclonal Antibodies Industry Forecast” looks at past sales and reviews total world Arthritis Monoclonal Antibodies sales in 2022, providing a comprehensive analysis by region and market sector of projected Arthritis Monoclonal Antibodies sales for 2023 through 2029. With Arthritis Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Arthritis Monoclonal Antibodies industry.
This Insight Report provides a comprehensive analysis of the global Arthritis Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Arthritis Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Arthritis Monoclonal Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Arthritis Monoclonal Antibodies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Arthritis Monoclonal Antibodies.
The global Arthritis Monoclonal Antibodies market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Arthritis Monoclonal Antibodies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Arthritis Monoclonal Antibodies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Arthritis Monoclonal Antibodies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Arthritis Monoclonal Antibodies players cover AbbVie Inc, F. Hoffmann-La Roche Ltd, Novartis, Johnson & Johnson(Janssen), Pfizer Inc, Mylan, Genentech, GSK and AstraZeneca PLC, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Arthritis Monoclonal Antibodies market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Remicade
Humira
Enbrel
Rituxan
Orencia
Actemra
Simponi
Cimzia
Segmentation by application
Rheumatoid Arthritis
Osteoarthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Fibromyalgia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie Inc
F. Hoffmann-La Roche Ltd
Novartis
Johnson & Johnson(Janssen)
Pfizer Inc
Mylan
Genentech
GSK
AstraZeneca PLC
LPI (LP Information)' newest research report, the “Arthritis Monoclonal Antibodies Industry Forecast” looks at past sales and reviews total world Arthritis Monoclonal Antibodies sales in 2022, providing a comprehensive analysis by region and market sector of projected Arthritis Monoclonal Antibodies sales for 2023 through 2029. With Arthritis Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Arthritis Monoclonal Antibodies industry.
This Insight Report provides a comprehensive analysis of the global Arthritis Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Arthritis Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Arthritis Monoclonal Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Arthritis Monoclonal Antibodies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Arthritis Monoclonal Antibodies.
The global Arthritis Monoclonal Antibodies market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Arthritis Monoclonal Antibodies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Arthritis Monoclonal Antibodies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Arthritis Monoclonal Antibodies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Arthritis Monoclonal Antibodies players cover AbbVie Inc, F. Hoffmann-La Roche Ltd, Novartis, Johnson & Johnson(Janssen), Pfizer Inc, Mylan, Genentech, GSK and AstraZeneca PLC, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Arthritis Monoclonal Antibodies market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Remicade
Humira
Enbrel
Rituxan
Orencia
Actemra
Simponi
Cimzia
Segmentation by application
Rheumatoid Arthritis
Osteoarthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Fibromyalgia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie Inc
F. Hoffmann-La Roche Ltd
Novartis
Johnson & Johnson(Janssen)
Pfizer Inc
Mylan
Genentech
GSK
AstraZeneca PLC
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Arthritis Monoclonal Antibodies Market Size 2018-2029
2.1.2 Arthritis Monoclonal Antibodies Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Arthritis Monoclonal Antibodies Segment by Type
2.2.1 Remicade
2.2.2 Humira
2.2.3 Enbrel
2.2.4 Rituxan
2.2.5 Orencia
2.2.6 Actemra
2.2.7 Simponi
2.2.8 Cimzia
2.3 Arthritis Monoclonal Antibodies Market Size by Type
2.3.1 Arthritis Monoclonal Antibodies Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Arthritis Monoclonal Antibodies Market Size Market Share by Type (2018-2023)
2.4 Arthritis Monoclonal Antibodies Segment by Application
2.4.1 Rheumatoid Arthritis
2.4.2 Osteoarthritis
2.4.3 Psoriatic Arthritis
2.4.4 Ankylosing Spondylitis
2.4.5 Fibromyalgia
2.4.6 Others
2.5 Arthritis Monoclonal Antibodies Market Size by Application
2.5.1 Arthritis Monoclonal Antibodies Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Arthritis Monoclonal Antibodies Market Size Market Share by Application (2018-2023)
3 Arthritis Monoclonal Antibodies Market Size by Player
3.1 Arthritis Monoclonal Antibodies Market Size Market Share by Players
3.1.1 Global Arthritis Monoclonal Antibodies Revenue by Players (2018-2023)
3.1.2 Global Arthritis Monoclonal Antibodies Revenue Market Share by Players (2018-2023)
3.2 Global Arthritis Monoclonal Antibodies Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Arthritis Monoclonal Antibodies by Regions
4.1 Arthritis Monoclonal Antibodies Market Size by Regions (2018-2023)
4.2 Americas Arthritis Monoclonal Antibodies Market Size Growth (2018-2023)
4.3 APAC Arthritis Monoclonal Antibodies Market Size Growth (2018-2023)
4.4 Europe Arthritis Monoclonal Antibodies Market Size Growth (2018-2023)
4.5 Middle East & Africa Arthritis Monoclonal Antibodies Market Size Growth (2018-2023)
5 Americas
5.1 Americas Arthritis Monoclonal Antibodies Market Size by Country (2018-2023)
5.2 Americas Arthritis Monoclonal Antibodies Market Size by Type (2018-2023)
5.3 Americas Arthritis Monoclonal Antibodies Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Arthritis Monoclonal Antibodies Market Size by Region (2018-2023)
6.2 APAC Arthritis Monoclonal Antibodies Market Size by Type (2018-2023)
6.3 APAC Arthritis Monoclonal Antibodies Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Arthritis Monoclonal Antibodies by Country (2018-2023)
7.2 Europe Arthritis Monoclonal Antibodies Market Size by Type (2018-2023)
7.3 Europe Arthritis Monoclonal Antibodies Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Arthritis Monoclonal Antibodies by Region (2018-2023)
8.2 Middle East & Africa Arthritis Monoclonal Antibodies Market Size by Type (2018-2023)
8.3 Middle East & Africa Arthritis Monoclonal Antibodies Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Arthritis Monoclonal Antibodies Market Forecast
10.1 Global Arthritis Monoclonal Antibodies Forecast by Regions (2024-2029)
10.1.1 Global Arthritis Monoclonal Antibodies Forecast by Regions (2024-2029)
10.1.2 Americas Arthritis Monoclonal Antibodies Forecast
10.1.3 APAC Arthritis Monoclonal Antibodies Forecast
10.1.4 Europe Arthritis Monoclonal Antibodies Forecast
10.1.5 Middle East & Africa Arthritis Monoclonal Antibodies Forecast
10.2 Americas Arthritis Monoclonal Antibodies Forecast by Country (2024-2029)
10.2.1 United States Arthritis Monoclonal Antibodies Market Forecast
10.2.2 Canada Arthritis Monoclonal Antibodies Market Forecast
10.2.3 Mexico Arthritis Monoclonal Antibodies Market Forecast
10.2.4 Brazil Arthritis Monoclonal Antibodies Market Forecast
10.3 APAC Arthritis Monoclonal Antibodies Forecast by Region (2024-2029)
10.3.1 China Arthritis Monoclonal Antibodies Market Forecast
10.3.2 Japan Arthritis Monoclonal Antibodies Market Forecast
10.3.3 Korea Arthritis Monoclonal Antibodies Market Forecast
10.3.4 Southeast Asia Arthritis Monoclonal Antibodies Market Forecast
10.3.5 India Arthritis Monoclonal Antibodies Market Forecast
10.3.6 Australia Arthritis Monoclonal Antibodies Market Forecast
10.4 Europe Arthritis Monoclonal Antibodies Forecast by Country (2024-2029)
10.4.1 Germany Arthritis Monoclonal Antibodies Market Forecast
10.4.2 France Arthritis Monoclonal Antibodies Market Forecast
10.4.3 UK Arthritis Monoclonal Antibodies Market Forecast
10.4.4 Italy Arthritis Monoclonal Antibodies Market Forecast
10.4.5 Russia Arthritis Monoclonal Antibodies Market Forecast
10.5 Middle East & Africa Arthritis Monoclonal Antibodies Forecast by Region (2024-2029)
10.5.1 Egypt Arthritis Monoclonal Antibodies Market Forecast
10.5.2 South Africa Arthritis Monoclonal Antibodies Market Forecast
10.5.3 Israel Arthritis Monoclonal Antibodies Market Forecast
10.5.4 Turkey Arthritis Monoclonal Antibodies Market Forecast
10.5.5 GCC Countries Arthritis Monoclonal Antibodies Market Forecast
10.6 Global Arthritis Monoclonal Antibodies Forecast by Type (2024-2029)
10.7 Global Arthritis Monoclonal Antibodies Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 AbbVie Inc
11.1.1 AbbVie Inc Company Information
11.1.2 AbbVie Inc Arthritis Monoclonal Antibodies Product Offered
11.1.3 AbbVie Inc Arthritis Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 AbbVie Inc Main Business Overview
11.1.5 AbbVie Inc Latest Developments
11.2 F. Hoffmann-La Roche Ltd
11.2.1 F. Hoffmann-La Roche Ltd Company Information
11.2.2 F. Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Product Offered
11.2.3 F. Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 F. Hoffmann-La Roche Ltd Main Business Overview
11.2.5 F. Hoffmann-La Roche Ltd Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Arthritis Monoclonal Antibodies Product Offered
11.3.3 Novartis Arthritis Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Johnson & Johnson(Janssen)
11.4.1 Johnson & Johnson(Janssen) Company Information
11.4.2 Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Product Offered
11.4.3 Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Johnson & Johnson(Janssen) Main Business Overview
11.4.5 Johnson & Johnson(Janssen) Latest Developments
11.5 Pfizer Inc
11.5.1 Pfizer Inc Company Information
11.5.2 Pfizer Inc Arthritis Monoclonal Antibodies Product Offered
11.5.3 Pfizer Inc Arthritis Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Pfizer Inc Main Business Overview
11.5.5 Pfizer Inc Latest Developments
11.6 Mylan
11.6.1 Mylan Company Information
11.6.2 Mylan Arthritis Monoclonal Antibodies Product Offered
11.6.3 Mylan Arthritis Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Mylan Main Business Overview
11.6.5 Mylan Latest Developments
11.7 Genentech
11.7.1 Genentech Company Information
11.7.2 Genentech Arthritis Monoclonal Antibodies Product Offered
11.7.3 Genentech Arthritis Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Genentech Main Business Overview
11.7.5 Genentech Latest Developments
11.8 GSK
11.8.1 GSK Company Information
11.8.2 GSK Arthritis Monoclonal Antibodies Product Offered
11.8.3 GSK Arthritis Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 GSK Main Business Overview
11.8.5 GSK Latest Developments
11.9 AstraZeneca PLC
11.9.1 AstraZeneca PLC Company Information
11.9.2 AstraZeneca PLC Arthritis Monoclonal Antibodies Product Offered
11.9.3 AstraZeneca PLC Arthritis Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 AstraZeneca PLC Main Business Overview
11.9.5 AstraZeneca PLC Latest Developments
12 Research Findings and Conclusion